“…Elotuzumab, a therapeutic anti-SLAMF7/CD319 antibody, induced dose-dependent ADCC activity toward BC2 target cells, using PBMCs as effector cells. Elotuzumab also enhanced granzyme B release from PBMC effector cells against BC2 cells [64]. Panaampon et al (2022) analyzed the expression of SLAMF7/CD319 by flow cytometry in a panel of primary effusion lymphoma cell lines (BCBL-1, BC-1, BC-2, BC-3, RM-P1, GTO, and TY-1), multiple myeloma cell lines (KMM-1, KMS-12-PE, RPMI-8226, U266, MM1.S, MM1.R, KMS-11, NCI-H929, JJN-3, and IM-9) and a mantle cell lymphoma (MCL) cell line (Z138) [65].…”